Regeneron Pharmaceuticals, Inc. (ETR:RGO)

Market Cap	69.03B
Revenue (ttm)	12.14B
Net Income (ttm)	3.90B
Shares Out	n/a
EPS (ttm)	35.45
PE Ratio	17.69
Forward PE	16.99
Dividend	3.40 (0.51%)
Ex-Dividend Date	Nov 20, 2025

Volume	25
Average Volume	99
Open	680.60
Previous Close	673.00
Day's Range	673.60 - 680.60
52-Week Range	464.70 - 688.20
Beta	n/a
RSI	80.81
Earnings Date	Feb 3, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: RGO

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD